Identification of dominant FOXE3 and PAX6 mutations in patients with congenital cataract and aniridia by Brémond-Gignac, Dominique et al.
Identification of dominant FOXE3 and PAX6 mutations in patients
with congenital cataract and aniridia
Dominique Brémond-Gignac,1 Pierre Bitoun,2 Linda M. Reis,3 Henri Copin,4 Jeffrey C. Murray,5
Elena V. Semina3,6
1Department of Pediatric Ophthalmology, St Victor University Hospital of Amiens, INSERM UMRS968, Vision Institute, Paris VI
University, Picardie Jules Verne University, Amiens, France; 2Department of Genetics, Jean Verdier Paris-Nord University
Hospital, APHP, Bondy, France; 3Department of Pediatrics and Children’s Research Institute at the Medical College of Wisconsin
and Children’s Hospital of Wisconsin, Milwaukee, WI; 4Department of Cytogenetics and Reproduction Biology, CGO University
Hospital of Amiens, Picardie Jules Verne University, Amiens, France; 5Department of Pediatrics, The University of Iowa, Iowa
City, IA; 6Department of Cell Biology, Neurobiology and Anatomy at the Medical College of Wisconsin, Milwaukee, WI
Purpose: Aniridia and congenital cataract represent rare but severe developmental ocular conditions. We examined 33
probands from France for mutations in several transcription factors associated with these phenotypes, the forkhead box
E3 (FOXE3), paired box gene 6 (PAX6), paired-like homeodomain transcription factor 2 (PITX2), and paired-like
homeodomain transcription factor 3 (PITX3) genes.
Methods: Out of 33 probands, 27 were affected with congenital cataract while the remaining six were affected with
aniridia (with or without cataract). The coding regions of FOXE3, PAX6, PITX2, and PITX3 were examined by direct
DNA sequencing of gene-specific PCR products.
Results: A novel dominant mutation at the stop codon of FOXE3, c.959G>C (p.X320SerextX72), was identified in a
patient with congenital cataract. Another novel FOXE3 sequence change, c.571–579dup (p.Tyr191_Pro193dup), was
identified in a patient with aniridia, mild lens opacities, and some additional ocular defects; this patient was also found to
carry a nonsense mutation in PAX6. PAX6 mutations were identified in two additional probands with aniridia and cataracts.
None of the observed sequence alterations were found in normal controls. No mutations were identified in PITX2 or
PITX3.
Conclusions: The p.X320SerextX72 mutation is only the fourth FOXE3 allele associated with a dominant phenotype
since the majority of FOXE3 mutations appear to be recessive with no phenotype observed in heterozygous carriers. The
encoded protein is predicted to contain a complete normal sequence followed by seventy-two erroneous amino acids; the
position and effect of this mutation are similar to two of the previously reported dominant changes, suggesting a common
mechanism for dominant alleles. The p.Tyr191_Pro193dup is predicted to result in an in-frame duplication of three amino
acids; however, the contribution of this mutation to the phenotype is unclear since the affected patient also carries a
nonsense mutation in PAX6 which acts upstream of FOXE3 in the molecular pathway. The identified PAX6 mutations
correspond to the two most commonly observed mutant alleles and demonstrate phenotypes that are consistent with the
previously reported spectrum.
Aniridia and congenital cataract represent rare but severe
ocular  conditions  reflecting  abnormal  development  of  the
anterior segment of the eye. Aniridia is characterized by the
congenital absence of the iris and is most commonly inherited
as an autosomal-dominant disorder. Aniridia is a panocular
disease  often  associated  with  additional  ocular  symptoms
such as visual impairment and nystagmus [1]. Congenital
cataract is an opacification of the ocular lens present at birth.
Congenital  cataract  is  usually  hereditary  and  can  be
transmitted as a dominant or a recessive trait. Congenital
cataracts are frequently accompanied by other ocular defects,
particularly  anterior  segment  anomalies  including  corneal
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limbal deficiency and glaucoma with goniodysgenesis, but
also posterior segment anomalies such as foveal hypoplasia
[2]. The complexity of anterior segment phenotypes is likely
due  to  close  interaction  of  corresponding  tissues  during
development and/or sharing of genetic factors that underlie
their proper differentiation. Mutations in transcription factors
that  play  active  roles  in  directing  normal  embryonic
developmental patterning were shown to result in a spectrum
of  anterior  segment  anomalies  including  aniridia  and
cataracts.
Mutations  in  forkhead  box  E3  (FOXE3),  a  forkhead
transcription factor expressed in the lens which is located at
chromosome 1p32, have been associated with both recessive
and  dominant  ocular  disease.  Dominant  mutations  in
FOXE3 have been seen in patients with congenital cataract
and/or  anterior  segment  disease;  three  dominant  disease-
causing  mutations  have  been  reported  to  date  [3-5].
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1705Meanwhile,  recessive  mutations  in  FOXE3  have  been
identified in eight families with aphakia, microphthalmia, and
sclerocornea  as  the  principal  phenotype  [5-8].  Obligate
carriers in all recessive families were unaffected with the
exception of one parent who was reported to have unilateral
ocular ‘cloudiness’ [7].
Paired box gene 6 (PAX6) is a transcriptional regulator
located  at  chromosome  11p13.  Mutations  or  deletions  of
PAX6 were first identified in patients with aniridia [9,10].
While aniridia remains the predominant phenotype associated
with  PAX6  mutations  [11],  related  ocular  phenotypes
including anterior segment malformations such as Peters’s
anomaly  [12],  keratitis  [13],  foveal  hypoplasia  [14],
congenital cataract [15], and optic nerve defects [16] were also
shown to be associated with PAX6 deficiency. Nonocular
defects  include  abnormal  brain  structure,  central  auditory
function,  and  olfactory  bulb  development  [17-19].  Two
patients  with  Gillespie-like  syndrome  (iris  hypoplasia/
aniridia,  tremor/ataxia,  and  learning  disability/mental
retardation) were also found to have mutations in PAX6 [20,
21]. In addition, WAGR syndrome (Wilms tumor, Aniridia,
Genitourinary  anomalies,  and  mental  Retardation)  is
associated with a contiguous gene deletion which includes
PAX6 and the WT1 gene (WT1) [22]. A recent review of
PAX6  mutations  in  the  Human  PAX6  Mutation  Database
[23]  found  that  mutations  which  lead  to  a  premature
termination codon are generally associated with aniridia while
missense mutations typically result in other related ocular
phenotypes  [11].  This  review  also  identified  four  CpG
dinucleotides  which  are  mutation  hotspots  accounting  for
21% of mutations in the database and all resulting in aniridia
[11].
Paired-like homeodomain transcription factor 2 (PITX2)
is a homeodomain transcription factor at chromosome 4q25.
Mutations  in  PITX2  were  first  reported  in  patients  with
Axenfeld-Rieger syndrome [24]. Subsequently, the associated
phenotypes have been expanded to include partial aniridia
[25],  Peters’  anomaly  [26],  iris  hypoplasia/
iridogoniodysgenesis syndrome [27,28], and ring dermoid of
the cornea [29]. A wide range of mutations have been reported
including  missense,  nonsense,  splice-site,  and  intragenic
deletions/duplications, along with whole gene deletions and
translocations  upstream  of  PITX2;  the  majority  of  these
mutations result in Axenfeld-Rieger syndrome [30].
Mutations  in  paired-like  homeodomain  transcription
factor 3 (PITX3), another homeodomain transcription factor
located at chromosome 10q25, are associated with autosomal
dominant congenital cataract with or without anterior segment
dysgenesis  [31].  A  recurrent  17-bp  insertion  (c.
657_673dup17) in the COOH-terminal region in the gene is
the most common mutation, resulting primarily in congenital
posterior polar cataract along with highly variable anterior
segment  mesenchymal  dysgenesis  (ASMD)  in  some
individuals [31-35]. Two additional heterozygous mutations
associated with isolated cataract have been reported [31,32,
36];  one  of  these  mutations,  c.650delG,  was  also  seen  in
homozygous  form  in  one  family,  resulting  in  severe
microphthalmia with neurologic deficits [36].
In this study, we screened thirty-three unrelated patients
affected with congenital cataract and/or aniridia for mutations
in FOXE3, PAX6, PITX2, and PITX3. Causative mutations
were  identified  in  FOXE3  and  PAX6  but  not  PITX2  or
PITX3.
METHODS
The  human  studies  were  approved  by  Paris  7  University
Hospital and the Institutional Review Boards of the Children’s
Hospital of Wisconsin and the University of Iowa Hospitals
and Clinics and informed consent was obtained for every
subject.  We  screened  a  population  of  33  probands  from
France: 27 were affected with congenital cataract while the
remaining six were affected with aniridia (with or without
cataract).
Gene-specific  products  were  generated  using  the
previously reported primers and conditions for FOXE3 [3],
PAX6 [37], PITX2 [24], and PITX3 [31]. Briefly, PCR  was
conducted in 30 μl reactions containing 40 ng DNA, Biolase
Reaction Buffer (Bioline, Taunton, MA), 0.25 mmol/l each
dNTP, 1.5 units Biolase DNA polymerase (Bioline) and 0.2
micromol/l of each oligodeoxynucleotide primer.  Cycling
profile included one cycle of 94 °C for 5 min followed by 30
cycles of 94 °C for 45 s, 55-60 °C (please see Table 1 for
annealing temperature and other details) for 45 s, and 72 °C
for 45 s, and one cycle of 72 °C for 10 min. The coding regions
of FOXE3, PAX6, PITX2, and PITX3 were examined by direct
DNA sequencing of PCR products, as previously described
[38]. Briefly, PCR products were sequenced in both directions
using Big Dye Terminator v3.1 (Applied Biosystems, Foster
City,  CA)  using  a  3730XL  DNA  Analyzer  (Applied
Biosystems). Chromatograms were examined manually and
all initially identified changes were confirmed by additional
independent PCR and sequencing experiments. One hundred
eighty two samples from healthy individuals of Caucasian
decent were examined for the changes observed in FOXE3
and  PAX6  using  SSCP  (single  strand  conformational
polymorphism) analysis along with the corresponding patient
samples as positive controls. In addition to this, the previously
reported FOXE3 normal variation data [7] and PAX6 variation
summarized in the Human PAX6 Mutation Database [23]
were used for comparisons.
RESULTS
Screening of FOXE3 identified a mutation in the stop codon
of FOXE3, c.959G>C (p.X320SerextX72), in Patient 1 with
congenital cataract (Figure 1A). There was no family history
of ocular disease and no other family members were available
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1706for testing. The mutation results in a change of the termination
codon into serine leading to the addition of 72 erroneous
amino acids to the end of the protein. No other changes in
FOXE3 were identified in this patient. A second sequence
alteration in FOXE3 was identified in Patient 2 affected with
aniridia, corneal limbal insufficiency, nystagmus, severe axile
myopia, mild lens opacities, and development of a fibrous
posterior capsular reaction after lens surgery (Figure 2). This
FOXE3  variant,  c.571–579dup  (p.Tyr191_Pro193dup),
results in an in-frame duplication of 3 amino acids (Figure 1B
and Figure 3A). The same patient was later found to also carry
a PAX6 mutation (see below). the parents of Patient 2 appear
to be unaffected but were not available for testing. Neither of
the identified FOXE3 variants was seen in 182 Caucasian
control individuals nor the previously reported 332 controls
of mixed ethnicity [7].
Mutations in PAX6 were identified in three unrelated
probands with aniridia and cataract. Patient 2 (also carrying
FOXE3 mutation, please see above) was found to have a c.
718C>T (p.Arg240X) mutation in PAX6. Patient 3, affected
with aniridia and congenital cataract, was found to carry the
same  mutation.  Finally,  Patient  4,  with  aniridia  and  mild
cataract,  was  found  to  carry  a  c.607C>T  (p.Arg203X)
mutation.  The  mother  of  Patient  4  also  has  aniridia  and
cataract  but  was  not  available  for  testing.  Both  of  these
mutations were previously reported in patients with aniridia
(The Human PAX6 Mutation Database) [11]. No mutations
in PITX2 or PITX3 were identified in this group of patients.
DISCUSSION
Mutation analysis of DNA obtained from patients affected
with congenital cataracts (27) and aniridia with or without
TABLE 1. PCR PRIMERS AND CONDITIONS.
Set Forward primer Reverse primer Gene region
Annealing
temperature
(°C)
Product
size (bp)
FOXE3 primers [3]
1 tgtccatataaagcgggtcg atgtacgagtagggcggctt Exon 1 (N-terminus) 56 298
2 ttctctggcttccctgccct tcggtgatgaagcggtagat Exon 1 (N-terminus, forkhead domain) 57 271
3 aagccgccctactcgtacat tcgttgagcgtgagattgtg Exon 1 (Forkhead domain) 56 170
4 ttcatcaccgaacgctttgc aggaagctgccgttgtcgaa Exon 1 (Forkhead domain) 56 185
5 aagggcaactactggacgct tagctccggctgcaggttca Exon 1 (Forkhead domain, C-terminus) 55 267
6 tctgttcagcgtcgacagc acaggtcgcacaggtgcct Exon 1 (C-terminus) 55 352
PAX6 primers [37]
1 ctcatttcccgctctggttc aagagtgtgggtgaggaagt Exon 1 60 197
2 ttatctctcactctccagcc aagcgagaagaaagaagcgg Exon 2 60 276
3 tcagagagcccatcgacgtat ctgtttgtgggttttgagcc Exon 3 60 193
4 ttgggagttcaggcctacct gaagtcccagaaagaccaga Exon 4 60 153
5 cctcttcactctgctctctt atgaagagagggcgttgaga Exon 5 60 257
5a tgaaagtatcatcatatttgtag gggaagtggacagaaaacca Exon 5a 55 237
6 gtggttttctgtccacttcc aggagagagcattgggctta Exon 6 60 299
7 caggagacactaccatttgg atgcacatatggagagctgc Exon 7 60 252
8 gggaatgttttggtgaggct caaagggccctggctaaatt Exon 8 60 371
9 gtagttctggcacaatatgg gtactctgtacaagcacctc Exon 9 60 206
10 gtagacacagtgctaacctg cccggagcaaacaggtttaa Exon 10 60 243
11 ttaaacctgtttgctccggg ttatgcaggccaccaccagc Exon 11 60 208
12 gctgtgtgatgtgttcctca tgcagcctgcagaaacagtg Exon 12 60 227
13 catgtctgtttctcaaaggga gaacaattaacttttgctggcc Exon 13 55 957
PITX2 primers [24]
1a ttggctcctaagtgcccc ccagactcgcattatctcac Exon 1a 56 596
1b cttgacacttctctgtcagg aagcgggaatgtctgcagg Exon 1b 56 667
2 tagtctcatctgagccctgc cactggcgatttggttctga Exon 2 56 282
3 acgcctctctccgcacgt ttcttgcgctttcgcccga Exon 3 56 258
4 cagctcttccacggcttct ttctctcctggtctacttgg Exon 4 56 374
5a gtaatctgcactgtggcatc ctgtgggtgcggctcaca Exon 5 56 627
5b ctgagactgaaagcaaagca ctcccatgaaataaaacacattt Exon 5 56 787
PITX3 primers [31]
1 cctggtctgccataaagtga attctcgacctgttcccaag Exon 1 55 343
2 acgcagccccagctttac aagccagcgcatattctcc Exon 2 55 395
3 gtgcaggacataacagcttc gagcagaggctggaggttg Exon 3 55 528
4a ctctagccacctcatctcg aggcataagggcaggacac Exon 5 55 524
4b agacctttccattcgccttc agtcaaaatgaccccagtcc Exon 5 55 483
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1707cataracts (6) identified two novel variants in FOXE3. One of
these  variants,  p.X320SerextX72,  apparently  represents  a
causative mutation responsible for a phenotype of dominant
congenital  cataract,  while  the  other  variant,
p.Tyr191_Pro193dup, is of unknown significance. Mutations
in FOXE3 appear to explain ~4% of congenital cataract cases
in this population.
The p.X320SerextX72 mutation in FOXE3 is only the
fourth mutant allele associated with a dominant phenotype
since the majority of FOXE3 mutations appear to be recessive
with no phenotype observed in heterozygous carriers (Figure
3B)  [3-8].  The  location  and  the  predicted  effect  of  this
mutation are consistent with two of the previously described
dominant mutations in FOXE3: p.Leu315AlafsX117 [3] and
p.X320ArgextX72 [5] (Figure 3B). All three mutations are
predicted to result in the addition of numerous erroneous
amino acids to the most distant end of the FOXE3 protein.
Two of these mutations, p.X320SerextX72 (reported here)
and p.X320ArgextX72 [5], affect the stop codon and therefore
are predicted to retain the entire normal FOXE3 sequence. The
similarity  between  these  mutations  suggests  a  possible
common  mechanism  for  FOXE3  dominant  alleles.  An
additional dominant mutation which affects the DNA-binding
domain of FOXE3 has also been reported (p.Arg90Leu [4]).
The congenital cataract phenotype observed in the patient
carrying the p.X320SerextX72 allele (Patient 1) is consistent
with other dominant FOXE3 mutations. The initially reported
p.Leu315AlafsX117 mutation was found in a patient and her
Figure  1.  Novel  FOXE3  mutations.
Fragments  of  DNA  sequence  trace
chromatograms corresponding to the c.
959G>C (p.X320SerextX73) mutation
in Patient 1(A) and the c.571–579dup
(p.Tyr191_Pro193dup)  variant  in
Patient 2 (B). Mutation sites indicated
with arrows.
Figure  2.  Patient  photograph.
Photographic image of the eye of Patient
2.
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1708mother with cataracts and posterior embryotoxon; the proband
was also affected with myopia [3]. The p.X320ArgextX72
mutation was identified in a family with a highly variable
phenotype:  the  proband  was  affected  with  bilateral
microphthalmia with aphakia and sclerocornea in the right eye
and Peters’s anomaly and congenital cataract in the left while
her mother and uncle had bilateral early onset cataract (age of
diagnosis not given) with iris colobomas also seen in the
uncle. A maternal aunt had a cataract extraction in her 20s and
the maternal grandmother had a cataract extraction in her 40s.
All of the above family members were found to carry the
mutation while an unaffected maternal uncle did not carry the
mutation  [5].  Finally,  the  p.Arg90Leu  dominant  mutation
affecting the DNA-binding domain of FOXE3 was associated
with  Peters’  anomaly  and  glaucoma,  but  not  cataract  [4].
There was a family history of the disease consistent with
dominant  inheritance  but  no  other  family  members  were
available for testing. In general, the phenotype associated with
dominant  mutations  is  milder  than  the  recessive  FOXE3
phenotype (microphthalmia with aphakia in many cases), with
the exception of the proband reported by Iseri et al. [5].
The  effect  of  the  p.Tyr191_Pro193dup  mutation  in
FOXE3 is unclear since Patient 2 also carries the nonsense
mutation in PAX6. The patient does demonstrate mild anterior
segment dysgenesis and lens opacities, but these features are
not  inconsistent  with  the  PAX6  mutation  [11].  Since  the
identified PAX6 mutation has been previously reported as
causative in many families and since Pax6 has been shown to
act  upstream  of  Foxe3  in  the  ocular  pathway  [39],  the
phenotype of this patient is apparently caused by the PAX6
deficiency. The effect of the p.Tyr191_Pro193dup mutation,
if any, is most likely masked by this earlier molecular defect.
It is also possible that this variant does make a contribution to
the  observed  phenotype  that  is  difficult  to  dissect  in  the
presence of the PAX6 mutation, or that it represents a very rare
polymorphism. This case emphasizes the importance of the
exclusion of mutations in major known genes in mutation
screens  to  ensure  accurate  identification  of  the  causative
allele.
The identified mutations in PAX6 are consistent with the
associated  phenotypes.  These  mutations,  c.718C>T
(p.Arg240X) and c.607C>T (p.Arg203X), are two of the most
common mutations, both affecting a CpG mutational hotspot
[11]. Of the 31 patients with the p.Arg240X mutation reported
in the Human PAX6 Mutation Database, 26 have isolated
aniridia  while  the  remaining  five  have  associated  ocular
anomalies (four with cataract). Of the 23 patients with the
p.Arg203X mutation in the database, 18 are reported to have
Figure 3. Summary of FOXE3 mutations. A: Alignment of FOXE3 proteins showing region of p.Tyr191-Pro193 duplication. Please note two
YAP amino acid motifs present in normal human and cow FOXE3 proteins and an additional insertion of this motif identified in Patient 2.
B: Schematic drawing of FOXE3 protein with human mutations. Forkhead domain is shown in dark gray. Mutations resulting in recessive
phenotypes are indicated with black arrows while mutations causing dominant disease- with blue arrows. The variant identified in Patient 2
is indicated with a gray arrowhead below the protein. Recurrent mutations are denoted with extended arrows. Positions of mutations identified
in this study are shown with asterisks.
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1709isolated aniridia and the remaining five have associated ocular
anomalies (one with cataract).
The absence of PITX2 mutations in examined patients is
not surprising given its limited contribution to aniridia and a
strong association with syndromic versus isolated anterior
segment phenotypes. As for PITX3, which is linked primarily
with cataracts with or without anterior segment defects, our
findings suggest that it is not a major cause of congenital
cataract.
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